Inovio Pharma (INO) Tops Q4 EPS by 6c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 +2.65%
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Note: EPS may not be comparable
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.53 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Lamb Weston (LW) Tops Q1 EPS by 15c ; Offers Guidance
- APA Corporation releases Q3 2026 preliminary financial data
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
